Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$21.89 -10.03%

-$3.24 today

Market cap
$3.71B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 2.75M

Average 3.67M

TNGX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Tango Therapeutics, Inc.NASDAQ: TNGX

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income turns negative

Q3 FY2026 net income was -$68.39M, compared with $15.88M a year earlier. Trailing-twelve-month net income was -$208M. Over 3 fiscal years it compounded at -2.1% a year.

Context

  • Net income amounted to 162.9% of revenue in FY2025, down 146.9 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 8 analysts of -$171.13M (+68.4%) for the fiscal year ending Dec 2026, a step up from the -22.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$68.39M+23.6% QoQ
Last fiscal yearDec 2025
-$101.59M-22.0% YoY
LTMSep 2026
-$208M+106.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-530.6%+89.0%+619.5 pp
1 year-22.0%+68.4%+90.5 pp
3-year CAGR-2.1%+32.5%+34.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(101.59M) USD
Year-over-year change
+22.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TNGX compares with its peers on the latest reported figures

  • TNGX's LTM Sep 2026 net income of $208M is the 5th largest of the 11 companies compared; the peer median is $90.8M.
  • Its year-over-year change of +106.9% is the 5th highest of 11, against a peer median of -2.9%.
  • Over three fiscal years its annual growth of -2.1% compares with a peer median of +6.0%.
TNGX Competitors Peer median
Net Income for TNGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$1.77B +117.8%+65.7%—
ERASErasca, Inc.LTM Sep 2026$307.94M +141.2%-20.0%—
NRIXNurix Therapeutics, Inc.LTM Aug 2026$294.88M +220.5%+13.6%42.0%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$286.04M -8.2%-1.6%2763.6%
TNGXTango Therapeutics, Inc.LTM Sep 2026$208M +106.9%-2.1%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$140.06M -54.4%+24.7%62.2%
NUVBNuvation Bio Inc.LTM Jun 2026$112.24M +155.3%+25.2%66.1%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$103.8M +0.5%-6.4%297.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$77.8M -39.1%-4.8%465.3%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$77.27M -7.7%+35.7%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M -6.4%-12.0%266.9%
Peer median (excluding TNGX) $90.8M-2.9%+6.0%266.9%

Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.24M)(108.18M)(101.74M)(130.3M)(101.59M)
Depreciation & Amortization897K1.61M2.42M2.5M2.28M
Deferred Income Tax00000
Stock-Based Compensation7.83M14.23M19.08M28.9M26.43M
Change in Working Capital(11.35M)(18.49M)(37.97M)(31.75M)(67.2M)
Accounts Receivables002M00
Inventory00000
Accounts Payables1.23M1.1M(1.71M)(1.18M)(825K)
Other Working Capital(12.58M)(19.59M)(38.26M)(30.56M)(66.37M)
Other Non-Cash Items1.32M1.75M234K(849K)1.2M
Operating Cash Flow(59.53M)(109.08M)(117.98M)(131.5M)(138.89M)
Capital Expenditures(1.84M)(7.69M)(1.53M)(754K)(1.05M)
Acquisitions (Net)00000
Purchases of Investments(372.36M)(208.5M)(310.57M)(240.89M)(264.46M)
Sales of Investments190.76M242.6M353.53M327.77M224.64M
Other Investing Activities00000
Investing Cash Flow(183.43M)26.4M41.43M86.13M(40.87M)
Debt Repayment342.11M0000
Common Stock Issued0080.02M41.72M222.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(14.78M)1.62M2.39M5.94M(36K)
Financing Cash Flow357.33M1.62M82.41M47.66M222.5M
Effect of Forex Changes00000
Net Change in Cash114.36M(81.07M)5.85M2.29M42.75M
Free Cash Flow(61.36M)(116.77M)(119.51M)(132.26M)(139.93M)

Tango Therapeutics, Inc.

NASDAQ:TNGX

Intrinsic Alpha fair value

Locked

Current Price

$21.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.